The Centre for Osteoarthritis Pathogenesis Versus Arthritis aims to develop new treatments for this disabling condition, improving healthcare and transforming people's lives.
Our strategy is to turn our research findings into patient benefit. This includes finding targets for new treatments, new tests or markers, and personalised approaches to symptom management for osteoarthritis.
Directed by Professor Tonia Vincent within the Kennedy Institute of Rheumatology, the OA Centre is hosted by the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford.
We bring together researchers and clinicians from across the University of Oxford including the Kennedy Institute of Rheumatology, the Botnar Research Centre, and the Nuffield Orthopaedic Centre, as well as Queen Mary University of London, King's College London and MRC Mutagenesis Unit, Harwell.
In addition to developing novel disease "markers" and therapies for patients with osteoarthritis, we are also creating a national training resource for scientists and clinicians working within the OA field.
The Centre was created in April 2013 with substantial funding from Versus Arthritis, the University of Oxford and the Kennedy Trust for Rheumatology Research (KTRR). A further five years funding was awarded in 2018.
Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis.
von Loga IS. et al, (2019), Ann Rheum Dis, 78, 672 - 675
Towards prevention of post-traumatic osteoarthritis: report from an international expert working group on considerations for the design and conduct of interventional studies following acute knee injury.
Watt FE. et al, (2019), Osteoarthritis Cartilage, 27, 23 - 33
Vincent TL. and Wann AKT., (2019), J Physiol, 597, 1271 - 1281
Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ.
Tang X. et al, (2018), Ann Rheum Dis, 77, 1372 - 1380
Vincent T. and Malfait A-M., (2017), Osteoarthritis Cartilage, 25, 351 - 353
Acute Molecular Changes in Synovial Fluid Following Human Knee Injury: Association With Early Clinical Outcomes.
Watt FE. et al, (2016), Arthritis Rheumatol, 68, 2129 - 2140
12 March 2019
Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.
18 September 2018
International expert working group develop first pre-guidelines for conducting robust studies aimed at prevention of osteoarthritis (OA) after acute knee injury.
30 April 2018
Researchers at NDORMS have found that many more patients could be given a partial knee replacement instead of a total knee replacement, resulting in improvements in their quality of life and lower costs for the healthcare system.
21 February 2018
An off-label drug prescribed to treat osteoarthritis of the hand when conventional medication has failed is ineffective, according to new research.